Cyclooxygenase-2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines. Methods: Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines. Results: Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity. Conclusions: This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.
Abstract
Background: The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines. Methods: Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines. Results: Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity. Conclusions: This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.
참고문헌 (30)
- Jemal A, "Cancer statistics, 2007", CA Cancer J Clin, 57, pp.43~66 (2007)
- Kovacs G, "The Heidelberg classification of renal cell tumours", J Pathol, 183, pp.131~133 (1997)
- Ljungberg B, "Renal cell carcinoma guideline", Eur Urol, 51, pp.1502~1510 (2007)
- Rizzo MT, "Cyclooxygenase-2 in oncogenesis", Clin Chim Acta, 412, pp.671~687 (2011)
- Fosslien E., "Molecular pathology of cyclooxygenase-2 in neoplasia", Ann Clin Lab Sci, 30, pp.3~21 (2000)
- Fosslien E, "Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis", Ann Clin Lab Sci, 31, pp.325~348 (2001)
- Karim A, "Cyclooxygenase-2 expression in brain metastases", Anticancer Res, 25, pp.2969~2971 (2005)
- Hara S, "Expression of cycloxygenase-2 in human bladder and renal cell carcinoma", Adv Exp Med Biol, 507, pp.123~126 (2002)
- Witton CJ, "Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer", Histopathology, 45, pp.47~54 (2004)
- Herceg ME, "Cyclooxygenase 2 expression in soft tissue leiomyosarcoma", Anticancer Res, 29, pp.2913~2917 (2009)
- Kim H, "Strong cytoplasmic expression of COX2 at the invasive fronts of gallbladder cancer is associated with a poor prognosis", JOURNAL OF CLINICAL PATHOLOGY, 63, pp.1048~1053 (2010), B M J PUBLISHING GROUP
- Kim SK, "Overexpression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in vitro", Oncol Rep, 12, pp.403~409 (2004)
- Masferrer JL, "Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors", Cancer Res, 60, pp.1306~1311 (2000)
- Shinohara N, "Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma", Jpn J Clin Oncol, 39, pp.720~726 (2009)
- Yoshimura R, "The effects of cyclooxygenase-2 inhibitors on urological cancer cells", Int J Mol Med, 13, pp.789~793 (2004)
- Khan Z, "Biology of Cox-2: an application in cancer therapeutics", Curr Drug Targets, 12, pp.1082~1093 (2011)
- Miyata Y, "Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival", Clin Cancer Res, 9, pp.1741~1749 (2003)
- Ronkainen H, "HuR expression is a marker of poor prognosis in renal cell carcinoma", Tumour Biol, 32, pp.481~487 (2011)
- Kankuri-Tammilehto MK, "Prognostic evaluation of COX-2 expression in renal cell carcinoma", Anticancer Res, 30, pp.3023~3030 (2010)
- 조대성, "Cyclooxygenase-2 and p53 Expression as Prognostic Indicators in Conventional Renal Cell Carcinoma", Yonsei Medical Journal, 46(1), pp.133~140 (2005), 연세대학교의과대학
- Edge SB, "The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM", Ann Surg Oncol, 17, pp.1471~1474 (2010)
- Fuhrman SA, "Prognostic significance of morphologic parameters in renal cell carcinoma", Am J Surg Pathol, 6, pp.655~663 (1982)
- Soslow RA, "COX-2 is expressed in human pulmonary, colonic, and mammary tumors", Cancer, 89, pp.2637~2645 (2000)
- Rini BI, "Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma", Cancer, 106, pp.566~575 (2006)
- Tuna B, "Significance of COX-2 expression in human renal cell carcinoma", Urology, 64, pp.1116~1120 (2004)
- Yoshimura R, "Study of cyclooxy genase-2 in renal cell carcinoma", Int J Mol Med, 13, pp.229~233 (2004)
- Mungan MU, "Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma", Eur Urol, 50, pp.92~97 (2006)
- Chen Q, "Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line", J Urol, 172(6 Pt 1), pp.2153~2157 (2004)
- Chen Q, "Significance of COX-2 expression in human renal cell carcinoma cell lines", Int J Cancer, 108, pp.825~832 (2004)
- Sato N, "Enhancement of the sensitivity of renal cell carcinoma cells to fas-mediated cytotoxicity and apoptosis by the selective cyclooxygenase-2 inhibitor JTE-522", Urol Int, 84, pp.362~368 (2010)